NCT02200211

Brief Summary

The purpose of the study is to compare the effectiveness of 1 hour/day of binocular game play 7 days per week with 2 hours/day patching 7 days per week in children 5 to \<17

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
485

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2014

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 23, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 25, 2014

Completed
2 months until next milestone

Study Start

First participant enrolled

September 11, 2014

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 19, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 19, 2016

Completed
2.2 years until next milestone

Results Posted

Study results publicly available

October 15, 2018

Completed
Last Updated

February 27, 2019

Status Verified

February 1, 2019

Enrollment Period

1.9 years

First QC Date

July 23, 2014

Results QC Date

March 1, 2018

Last Update Submit

February 25, 2019

Conditions

Keywords

Amblyopia

Outcome Measures

Primary Outcomes (6)

  • Change in Distance Visual Acuity From Baseline in the Younger Cohort (5 to <13 Years)

    Monocular distance visual acuity (VA) in current refractive correction (if required) in each eye by a certified examiner using the electronic Amblyopia Treatment Study single-surround HOTV (ATS-HOTV) visual acuity protocol for children \<7 years and the Electronic Early Treatment Diabetic Retinoscopy Study (E-ETDRS) visual acuity protocol for children ≥ 7 years on a study-certified acuity tester displaying single surrounded optotypes. For the younger cohort, the level of visual acuity is analyzed in the log of the Minimum Angle of Resolution (logMAR) scale (approximate range: -0.2 to 1.7) such that higher scores indicate poorer VA. Change in VA is computed as logMAR lines (positive values indicate improvement), defined as the difference between the enrollment and 16-week acuities (logMAR) multiplied by 10.

    Baseline and 16 weeks

  • Mean Amblyopic Eye Visual Acuity (Younger Cohort)

    Monocular distance visual acuity (VA) in current refractive correction (if required) in each eye by a certified examiner using the electronic Amblyopia Treatment Study single-surround HOTV (ATS-HOTV) visual acuity protocol for children \<7 years and the Electronic Early Treatment Diabetic Retinoscopy Study (E-ETDRS) visual acuity protocol for children ≥ 7 years on a study-certified acuity tester displaying single surrounded optotypes. For the younger cohort, the level of visual acuity is analyzed in the log of the Minimum Angle of Resolution (logMAR) scale (approximate range: -0.2 to 1.7) such that higher scores indicate poorer VA.

    16 Weeks from baseline

  • Mean Change in Amblyopic-eye Visual Acuity in the Older Cohort (13 to <17 Years)

    Monocular distance visual acuity (VA) in current refractive correction (if required) in each eye by a certified examiner using the Electronic Early Treatment Diabetic Retinoscopy Study (E-ETDRS) visual acuity protocol for children ≥ 7 years on a study-certified acuity tester displaying single surrounded optotypes. For the analyses in the older cohort, the level of VA is measured as letter scores (approximate range: 0 to 97 letters, lower scores indicate poorer VA) and change in VA from baseline is measured in letters (positive values indicate improvement), defined as the difference in letter scores between enrollment and follow-up.

    Baseline and 16 weeks

  • Mean Amblyopic-eye Visual Acuity in the Older Cohort (13 to <17 Years)

    Monocular distance visual acuity (VA) in current refractive correction (if required) in each eye by a certified examiner using the Electronic Early Treatment Diabetic Retinoscopy Study (E-ETDRS) visual acuity protocol for children ≥ 7 years on a study-certified acuity tester displaying single surrounded optotypes. For the analyses in the older cohort, the level of VA is measured as letter scores (approximate range: 0 to 97 letters, lower scores indicate poorer VA) and change in VA from baseline is measured in letters (positive values indicate improvement), defined as the difference in letter scores between enrollment and follow-up.

    16 weeks

  • Distribution of Change in Amblyopic-eye Visual Acuity

    Monocular distance visual acuity (VA) in current refractive correction (if required) in each eye by a certified examiner using the electronic Amblyopia Treatment Study single-surround HOTV (ATS-HOTV) visual acuity protocol for children \<7 years and the Electronic Early Treatment Diabetic Retinoscopy Study (E-ETDRS) visual acuity protocol for children ≥ 7 years on a study-certified acuity tester displaying single surrounded optotypes. Younger cohort: The level of VA is analyzed in the log of the Minimum Angle of Resolution (logMAR) scale (previously defined) and change in VA from baseline as logMAR lines (previously defined). Older cohort: The level of VA is measured as letter scores (previously defined) and VA change from baseline is measured in letters (previously defined).

    Baseline and 16 weeks

  • Distribution of Amblyopic-eye Visual Acuity

    Monocular distance visual acuity (VA) in current refractive correction (if required) in each eye by a certified examiner using the electronic Amblyopia Treatment Study single-surround HOTV (ATS-HOTV) visual acuity protocol for children \<7 years and the Electronic Early Treatment Diabetic Retinoscopy Study (E-ETDRS) visual acuity protocol for children ≥ 7 years on a study-certified acuity tester displaying single surrounded optotypes. Younger cohort: The level of VA is analyzed in the log of the Minimum Angle of Resolution (logMAR) scale (previously defined) and change in VA from baseline as logMAR lines (previously defined). Older cohort: The level of VA is measured as letter scores (previously defined) and VA change from baseline is measured in letters (previously defined).

    At 16 weeks

Secondary Outcomes (12)

  • Number of Participants With Amblyopic-eye VA Improvement of 2 or More logMAR Lines (10 or More Letters if E-ETDRS) From Baseline

    Baseline and 16-week visit

  • Number of Participants With Resolution of Amblyopia

    16-week visit

  • Time Course of Visual Acuity Improvement

    Baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks

  • Younger Cohort: Change in Distance Visual Acuity From Baseline According to Subgroups

    Baseline and 16 weeks

  • Older Cohort: Change in Distance Visual Acuity From Baseline According to Subgroups

    Baseline and 16 weeks

  • +7 more secondary outcomes

Other Outcomes (10)

  • Percentage of Participants Reporting >75% of Prescribed Treatment Completed (Subjective Measures of Adherence)

    16 Weeks from baseline

  • Participants Who Received Non-protocol, Alternative Treatment During the Study

    Entire study period, up to 16 weeks

  • Safety Analysis: Distribution of the Change in Fellow-eye Visual Acuity From Baseline

    16-week visit

  • +7 more other outcomes

Study Arms (2)

Binocular Treatment

EXPERIMENTAL

Binocular computer game play 1 hour per day, 7 days per week (minimum of 4 days per week)

Device: iPad®

Patching Treatment

ACTIVE COMPARATOR

Patching 2 hours per day, 7 days per week

Other: Patching 2 hours per day, 7 days per week

Interventions

iPad®DEVICE

Binocular therapy on iPad®

Binocular Treatment
Also known as: Patching
Patching Treatment

Eligibility Criteria

Age5 Years - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age 5 to \<17 years
  • Amblyopia associated with strabismus, anisometropia, or both (previously treated or untreated)
  • Criteria for strabismus: At least one of the following must be met:
  • Presence of a heterotropia on examination at distance or near fixation (with or without spectacles)
  • Documented history of strabismus which is no longer present (which in the judgment of the investigator could have caused amblyopia)
  • Criteria for anisometropia: At least one of the following criteria must be met:
  • ≥0.50 diopter (D) difference between eyes in spherical equivalent
  • ≥1.50 D difference between eyes in astigmatism in any meridian
  • Criteria for combined-mechanism amblyopia: Both of the following criteria must be met:
  • Criteria for strabismus are met (see above)
  • ≥1.00 D difference between eyes in spherical equivalent OR ≥1.50 D difference between eyes in astigmatism in any meridian
  • Note: the spherical equivalent requirement differs from that in the definition for refractive/anisometropic amblyopia
  • No amblyopia treatment in the past 2 weeks (patching, atropine, Bangerter, vision therapy)
  • Refractive correction (spectacles or contact lenses, if applicable) must meet the following criteria at enrollment and be based on a cycloplegic refraction that is not more than 7 months old.
  • Requirements for Correction of Refractive Error:
  • +22 more criteria

You may not qualify if:

  • A subject is excluded for any of the following reasons:
  • Prism in the refractive correction at time of enrollment (eligible only if prism is discontinued 2 weeks prior to enrollment).
  • Myopia greater than -6.00 D spherical equivalent in either eye.
  • Previous intraocular or refractive surgery.
  • Any treatment for amblyopia (patching, atropine, Bangerter filter, or vision therapy) during the past 2 weeks. Previous amblyopia therapy is allowed regardless of type, but must be discontinued at least 2 weeks immediately prior to enrollment.
  • Ocular co-morbidity that may reduce visual acuity determined by an ocular examination performed within the past 7 months (Note: nystagmus per se does not exclude the subject if the above visual acuity criteria are met).
  • No Down syndrome or cerebral palsy
  • No severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Subjects with mild speech delay or reading and/or learning disabilities are not excluded.
  • Heterotropia or heterophoria with a total ocular deviation \>10∆ (phoria plus tropia \>10∆) at near (measured by PACT).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

Seattle Children's Hospital, University of Washington

Seattle, Washington, 98105, United States

Location

Related Publications (2)

  • Holmes JM, Manh VM, Lazar EL, Beck RW, Birch EE, Kraker RT, Crouch ER, Erzurum SA, Khuddus N, Summers AI, Wallace DK; Pediatric Eye Disease Investigator Group. Effect of a Binocular iPad Game vs Part-time Patching in Children Aged 5 to 12 Years With Amblyopia: A Randomized Clinical Trial. JAMA Ophthalmol. 2016 Dec 1;134(12):1391-1400. doi: 10.1001/jamaophthalmol.2016.4262.

  • Tailor V, Ludden S, Bossi M, Bunce C, Greenwood JA, Dahlmann-Noor A. Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to eight years. Cochrane Database Syst Rev. 2022 Feb 7;2(2):CD011347. doi: 10.1002/14651858.CD011347.pub3.

Related Links

MeSH Terms

Conditions

Amblyopia

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesVision DisordersSensation DisordersNeurologic ManifestationsEye DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Raymond Kraker, M.S.P.H., Director of PEDIG Coordinating Center
Organization
Jaeb Center for Health Research

Study Officials

  • Jonathan Holmes, MD

    Mayo Clinic

    STUDY CHAIR
  • Vivan Manh, OD

    University of Washington

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 23, 2014

First Posted

July 25, 2014

Study Start

September 11, 2014

Primary Completion

August 19, 2016

Study Completion

August 19, 2016

Last Updated

February 27, 2019

Results First Posted

October 15, 2018

Record last verified: 2019-02

Data Sharing

IPD Sharing
Will share

In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
After primary manuscripts are published
Access Criteria
Users accessing the data must enter an email address.

Locations